EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity.
Johannes Lorenz BergBianca PerflerStefan HatzlBarbara UhlAndreas ReinischGudrun PregartnerAndrea BergholdThomas PenzMichael K SchusterKlaus GeisslerAndreas ProkeschCarsten Muller-TidowGerald HoeflerKarl KashoferAlbert WölflerHeinz SillVeronica CaraffiniArmin ZebischPublished in: Leukemia (2021)